Globus Medical, Inc. $GMED Shares Purchased by Clearline Capital LP

Clearline Capital LP lifted its position in Globus Medical, Inc. (NYSE:GMED) by 342.5% in the third quarter, HoldingsChannel reports. The firm owned 148,472 shares of the medical device company’s stock after buying an additional 114,917 shares during the period. Clearline Capital LP’s holdings in Globus Medical were worth $8,503,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC raised its stake in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the period. Advisors Asset Management Inc. purchased a new stake in shares of Globus Medical in the 2nd quarter valued at approximately $28,000. First Horizon Corp purchased a new stake in shares of Globus Medical in the 3rd quarter valued at approximately $31,000. Parallel Advisors LLC increased its holdings in shares of Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after buying an additional 173 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Globus Medical during the 3rd quarter worth approximately $36,000. 95.16% of the stock is currently owned by institutional investors and hedge funds.

More Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research sharply raised EPS forecasts across multiple quarters and years and maintained a “Strong‑Buy” rating — the firm bumped Q1, Q2 and Q3 2027 estimates and raised FY2026 and FY2027 outlooks (FY2027 to $4.66). Improved analyst earnings trajectories support higher forward valuations and raise the bar for future guidance. Zacks Research Raises Earnings Estimates for Globus Medical
• Positive Sentiment: Brokerage consensus sits at an average “Moderate Buy” rating — this aggregate analyst view suggests continued institutional support and can attract momentum buying as earnings estimates move higher. Globus Medical Given Average Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: Technical/valuation context is mixed — GMED is trading above its 200‑day moving average (longer‑term support) but below its 50‑day average (shorter‑term momentum). The stock still trades at a mid‑teens to low‑20s P/E on forward estimates, so further upside may depend on continued estimate upgrades or stronger organic revenue/ margin beats. MarketBeat GMED Page

Globus Medical Stock Performance

NYSE:GMED opened at $84.81 on Friday. Globus Medical, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The company has a 50 day moving average price of $90.71 and a 200 day moving average price of $78.37. The stock has a market capitalization of $11.47 billion, a P/E ratio of 21.52, a PEG ratio of 1.99 and a beta of 1.05.

Globus Medical (NYSE:GMED) last announced its earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.22. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The company had revenue of $826.42 million for the quarter, compared to analyst estimates of $803.29 million. During the same quarter in the previous year, the company earned $0.84 earnings per share. The firm’s quarterly revenue was up 25.7% compared to the same quarter last year. Research analysts forecast that Globus Medical, Inc. will post 3.44 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Kyle Kline sold 3,594 shares of the firm’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $363,353.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Kelly Huller sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 35,594 shares of company stock valued at $3,332,253. 18.51% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently commented on the company. TD Cowen upgraded Globus Medical to a “strong-buy” rating in a report on Tuesday, January 27th. Morgan Stanley raised their target price on Globus Medical from $70.00 to $100.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Truist Financial set a $115.00 target price on Globus Medical in a research report on Wednesday, February 25th. Wall Street Zen raised Globus Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. Finally, Piper Sandler reiterated an “overweight” rating and set a $115.00 price target (up from $90.00) on shares of Globus Medical in a report on Thursday, January 8th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $104.36.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.